<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Download Champions' latest Tumor Models San Francisco 2025 Poster

 An Integrated Platform for Antibody-Drug Conjugate Discovery and Development

 

Tumor Model SF-Poster2025.pdf

Antibody-drug conjugates (ADCs) represent a cutting-edge cancer therapy that combines the specificity of monoclonal antibodies with the potency of small-molecule drugs. Champions Oncology has developed an advanced preclinical platform to address challenges in ADC development, including the limitations of traditional cell line systems. The platform integrates molecular profiling, multi-omics analysis, and functional assays with patient-derived xenograft (PDX) models from a repository of over 1,500 samples. It focuses on identifying and validating novel ADC targets, optimizing delivery mechanisms, and testing efficacy using ex vivo TumorGraft3D organoids, co-culture systems, and humanized mice models. Case studies on Enhertu (a HER2-targeting ADC) and a mouse clinical trial for a B7-H4-targeting ADC demonstrate the platform's ability to generate clinically translatable insights, paving the way for next-generation cancer treatments.

Poster's Key Highlights:

  • Comprehensive Preclinical Platform: Combines high-resolution molecular profiling, PDX models, and functional assays to ensure clinically relevant results.

  • Innovative ADC Testing: Employs advanced tools like TumorGraft3D organoids and humanized murine models to study target biology, internalization, and immune effects.

  • Proven Case Studies: Demonstrates translational success through Enhertu-resistant model testing and B7-H4-targeting ADC trials, aligning preclinical findings with clinical outcomes.








 

 

 

Download the Poster